BIM
BCLI

BlackRock Investment Management’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

BlackRock Investment Management’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$8K Hold
200
– – ﹤0.01% 3652
2016
Q3 		$7K Hold
200
– – ﹤0.01% 3694
2016
Q2 		$7K Hold
200
– – ﹤0.01% 3754
2016
Q1 		$8K Hold
200
– – ﹤0.01% 3687
2015
Q4 		$9K Buy
200
+24
+14% +$989 ﹤0.01% 3705
2015
Q3 		$6K Hold
176
– – ﹤0.01% 3862
2015
Q2 		$10K Buy
+176
New +$10.5K ﹤0.01% 3715

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 19.31% 1-Year Est. Return
PVH
Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

BlackRock Investment Management's BCLI Position: Q4 2016 in Review

BlackRock Investment Management held its BRAINSTORM CELL THERAPUTC (BCLI) position steady in Q4 2016 at 200 shares worth $8K. The position accounts for ﹤0.01% of the portfolio, ranked #3652.

BlackRock Investment Management first reported a position in BCLI in Q2 2015 and has held it in 7 quarters since. The position peaked at $10K in Q2 2015. 27 funds tracked by Wall St. Rank hold BCLI as of Q4 2016.

  • BlackRock Investment Management held 200 shares of BRAINSTORM CELL THERAPUTC worth $8K as of Q4 2016.
  • BlackRock Investment Management left its BRAINSTORM CELL THERAPUTC share count unchanged in Q4 2016.
  • BRAINSTORM CELL THERAPUTC made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #3652 holding.
  • BlackRock Investment Management first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2015 and has held it in 7 quarters since.
  • BlackRock Investment Management's BRAINSTORM CELL THERAPUTC position peaked at $10K in Q2 2015.
  • 27 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.